 |
 |
 |
| Daiichi Sankyo Jobs Profile This profile is a brief introduction for people seeking employment in pharmaceutical graduate jobs, pharmaceutical nurse advisors, pharmaceutical sales jobs, pharmaceutical training jobs, pharmaceutical sales management jobs, pharmaceutical marketing jobs, pharmaceutical executive jobs, or pharmaceutical clinical research associates who may be considering working for Daiichi Sankyo. Company OverviewThe business integration of DAIICHI and SANKYO brings together two pharmaceutical companies bound by a century of vision and a legacy of firsts. From the discovery of epinephrine to the development of the statin class of lipid-lowering agents, and the development of the first glitazone, which revolutionized long-term control of type 2 diabetes, the people of DAIICHI SANKYO remain committed to a unique ideal - a Global Pharma Innovator.
We believe good science walks hand-in-hand with humanity and, as we move forward into our next century, we seek to build on our history of discovery with the development of new therapies in cardiovascular disease, cancer, metabolic disorders and infection. Range of products DAIICHI SANKYO has its core expertise in the development of drugs for the treatment of cardiovascular disease (CVD), dyslipidemia and infectious diseases. Further important fields of research are oncology, immunology / allergy and bone / joint diseases. The following passage gives a short overview of our medicinal products. The DAIICHI SANKYO indication areas:
|
 Please contact the Account Manager for opportunities with this organisation News Daiichi Sankyo: Benicar reverses blood vessel damage Daiichi Sankyo has announced the publication of new data showing that Benicar (olmersartan medoxomil) reverses blood vessel damage in hypertension patients. Daiichi Sankyo becomes majority partner of Ranbaxy Daiichi Sankyo has announced that it has become a major partner of Indian generic pharmaceutical firm Ranbaxy Laboratories. Daiichi Sankyo reports bile discovery in diabetes patients Daiichi Sankyo and kineMed have announced the discovery of a key difference in bile acid metabolism in patients with type 2 diabetes that could suggest the existence of a newly-identified underlying d... Daiichi Sankyo drug 'significantly lowers blood glucose in diabetes patients' Daiichi Sankyo has announced the publication of data from two pooled analysis showing that Welchol (colesevelam HCL) used in combination with metformin or sulfonylurea-based therapy significantly lowe... Forest Laboratories and Daiichi Sankyo announce termination of Azor agreement Forest Laboratories and Daiichi Sankyo have announced that they have terminated their co-promotion agreement for Azor (amlodipine and olmesartan medoxomil). | ||||||||
